- Report
- August 2023
- 336 Pages
Global
From €5285EUR$5,500USD£4,518GBP
- Report
- July 2023
- 230 Pages
Global
From €4756EUR$4,950USD£4,066GBP
- Report
- April 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- May 2024
- 196 Pages
Global
From €4756EUR$4,950USD£4,066GBP
- Report
- November 2023
- 141 Pages
Global
From €2401EUR$2,499USD£2,053GBP
- Report
- February 2024
- 100 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- February 2024
- 176 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- October 2023
- 190 Pages
Global
From €4708EUR$4,900USD£4,025GBP
From €5717EUR$5,950USD£4,888GBP
From €6245EUR$6,500USD£5,339GBP
- Drug Pipelines
- April 2024
- 100 Pages
Global
From €2883EUR$3,000USD£2,464GBP
- Report
- August 2023
- 150 Pages
Global
From €4084EUR$4,250USD£3,491GBP
- Report
- November 2023
- 144 Pages
Global
From €4276EUR$4,450USD£3,656GBP
- Report
- February 2024
- 85 Pages
North America
From €4564EUR$4,750USD£3,902GBP
- Report
- July 2020
- 132 Pages
Global
From €1153EUR$1,200USD£986GBP
- Report
- April 2021
Global
From €865EUR$900USD£739GBP
- Report
- August 2020
- 150 Pages
Global
From €4084EUR$4,250USD£3,491GBP
- Report
- March 2019
- 90 Pages
Europe
From €4564EUR$4,750USD£3,902GBP
- Report
- October 2022
- 176 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- April 2020
- 119 Pages
Global
From €3517EUR$3,660USD£3,007GBP
The Oral Insulin market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs that are taken orally to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Oral Insulin is a relatively new form of treatment, and is seen as a more convenient and less invasive alternative to traditional insulin injections. It is also seen as a potential solution to the problem of poor adherence to insulin therapy.
Oral Insulin is still in the early stages of development, and there are currently no approved oral insulin products on the market. However, several companies are researching and developing oral insulin products, and some have already completed clinical trials. Companies in the Oral Insulin market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Pfizer. Show Less Read more